learn GT20029
research compound made to degrade androgen receptors in scalp
Search
forLearn
5 / 24 resultslearn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
learn Finasteride
Frontline, gold standard treatment for combatting androgenic alopecia
learn Procyanidin
bioflavonoid found in plants with antioxidant and hair stimulating properties
learn Melatonin
hormone commonly taken for sleep aid has some topical benefits for hair
Research
5 / 1000+ results
research A Top-Down Design Approach for Generating a Peptide PROTAC Drug Targeting Androgen Receptor for Androgenetic Alopecia Therapy
A new AI-driven method shows promise for treating hair loss with a peptide-based drug.
research Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery
Proteolysis-targeting chimeras (PROTACs) are being explored for topical use to achieve localized protein degradation with reduced systemic toxicity. This article discusses advances in topical PROTACs, highlighting androgen receptor degraders AH-001 and GT20029, which are in clinical trials for androgenetic alopecia, with GT20029 also being tested for acne. The scope of PROTACs is expanding to target proteins like JAK kinases and BET family members, with potential applications in dermatology, pulmonary and ocular diseases, and cosmetics. Innovative delivery methods, such as liposomes and microneedle systems, are enhancing local delivery. However, challenges remain in optimizing stability, tissue penetration, and target engagement. The article suggests strategic directions to advance the clinical application of topical PROTACs.
research Protac Degraders of Androgen Receptor-Integrated Dissolving Microneedles for Androgenetic Alopecia and Recrudescence Treatment via Single Topical Administration
A new hair loss treatment using dissolving microneedles was found to speed up hair growth and was more effective than daily use of common hair growth drugs.
research Discovery of a Novel Non-Invasive AR PROTAC Degrader for the Topical Treatment of Androgenetic Alopecia
A new topical treatment for hair loss shows promise by targeting androgen receptors.
research Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Adding a second method to PROTACs could improve cancer treatment.
Community Join
5 / 1000+ resultscommunity Protac degradation of the androgen receptor in mice shows good efficacy and no systemic drug could be found
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
community Kintor Pharmaceutical Announces AR-PROTAC (GT20029) Approved for Acne and Androgenic Alopecia Clinical Trials in China
The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.
community Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
community Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.